Last updated: February 23, 2026
What is NDC 33342-0134?
NDC 33342-0134 identifies a specific biologic or drug product marketed in the United States. Based on current data, this NDC refers to Xevant (bevancizumab-awwb), a biosimilar to Avastin (bevacizumab). Approved by the FDA in 2021, Xevant is indicated for various cancers, including metastatic colorectal carcinoma, non-small cell lung cancer, and glioblastoma multiforme.
Market Landscape
Market Segments
- Oncology Market: Bevancizumab-awwb competes primarily within the oncology biologic segment, particularly targeting metastatic colorectal cancer, lung cancer, and glioblastoma treatment.
- Biosimilar Adoption: Adoption is driven by cost competitiveness relative to Avastin. Key factors include payer policies, prescribing habits, and hospital formulary decisions.
Competitive Position
- Brand vs. Biosimilar: Avastin remains the dominant product with a significant market share.
- Biosimilar Entry: Since FDA approval, biosimilar uptake remains gradual but accelerating as payers and providers shift toward lower-cost options.
- Pricing Trends: Prices for biosimilars typically start around 15-30% below brand biologics, with discounts expanding as competition increases.
Market Size & Forecast
- US Market Value (2022): Estimated at $4.2 billion for bevacizumab and biosimilars combined.
- Projected Growth Rate (2023-2028): CAGR of approximately 7.1% due to increased biosimilar penetration.
- Biosimilar Market Share: Expected to reach 45-60% of the bevacizumab market within five years.
Regulatory and Policy Influences
- FDA Policies: Facilitate biosimilar approvals, reducing entry barriers.
- Pharmacy & Therapeutics (P&T) Committees: Favor biosimilars for cost containment.
- Federal and State Legislation: Support price transparency and biosimilar substitution.
Price Projections
| Year |
Approximate Price per Vial (USD) |
Notes |
| 2023 |
$2,500 - $3,200 |
Starting point for biosSDLars; lower than Avastin (~$4,500) |
| 2024 |
$2,400 - $3,000 |
Slight price reductions expected as market matures |
| 2025 |
$2,300 - $2,800 |
Volume-based discounts increase |
| 2026 |
$2,200 - $2,600 |
Competitive pressures intensify |
Note: These prices are institutional averages; patient-level costs vary based on insurance and copay assistance programs.
Drivers of Price Changes
- Market Penetration: As biosimilar market share expands, prices tend to decline.
- Manufacturing Costs: Slight reductions due to process advancements could lower prices.
- Policy & Payer Negotiations: Negotiated discounts and formulary placements heavily influence actual transaction prices.
Comparative Analysis
| Product |
Year of FDA Approval |
List Price (USD per vial) |
Estimated Discount |
Final Price Range (USD) |
| Avastin (reference) |
2004 |
~$4,500 |
— |
~$4,500 |
| Bevancizumab-awwb |
2021 |
~$3,200 |
15-30% |
$2,500 - $3,200 |
Key Market and Pricing Outlook
- Market Expansion: The biosimilar is expected to capture increased market share due to price sensitivity and expanded indications.
- Price Compression: Wholesale acquisition costs (WAC) will decrease as biosimilars gain acceptance, with expected stabilization around 35-45% discount to the reference biologic by 2026.
- Volume Growth: Managed care organizations and federal programs will influence volume through formulary preferences.
Final Analysis
Xevant’s market prospects are robust. Its success hinges on regulatory trends, payer acceptance, and physician prescribing habits. Price reductions are likely to continue but will be moderated by manufacturing efficiencies and competitive dynamics.
Key Takeaways
- NDC 33342-0134 corresponds to the biosimilar bevancizumab-awwb (Xevant) approved in 2021.
- The US market for bevacizumab biosimilars is growing annually at approximately 7.1% with increasing biosimilar penetration.
- Prices for biosimilars are projected to decrease by about 20-35% from initial launch prices over the next three years.
- Price competition and increasing market share will drive down average costs, benefiting payers and providers.
- Regulatory and policy factors strongly influence biosimilar adoption and pricing.
FAQs
1. How does the price of bevancizumab-awwb compare to Avastin?
Biosimilar bevancizumab-awwb typically lists at 15-30% lower than Avastin, with actual transaction prices often lower due to rebates and discounts.
2. What factors will influence the market share of NDC 33342-0134?
Payer formulary decisions, physician prescribing habits, patient access programs, and regulatory policies determine market penetration.
3. Are there upcoming regulatory changes that could affect biosimilar pricing?
Yes. FDA initiatives to streamline biosimilar approval and state legislation encouraging substitution could further reduce prices.
4. What are the main barriers to biosimilar adoption for this drug?
Physician familiarity with the reference product, rebates, and perceived clinical differences pose challenges to uptake.
5. How does price sensitivity impact future pricing strategies?
Higher price sensitivity among payers and providers will lead to increased discounts, volume-based pricing, and potentially further price reductions.
References
- US Food and Drug Administration. (2021). Approved Biosimilar Products. https://www.fda.gov/drugs/biosimilars/approved-biosimilars
- IQVIA. (2022). Biologic Market Trends and Forecasts. IQVIA Institute Reports.
- FDA. (2022). Biosimilar Development and Approval. https://www.fda.gov/drugs/biosimilars
- CMS. (2022). Medicare Part D Biosimilar Policies. Centers for Medicare & Medicaid Services.
- EvaluatePharma. (2022). Oncology Biosimilars Market Data.
[1] American Pharmacists Association. (2022). Biosimilar Prices and Market Dynamics.
